Study of Atezolizumab in Advanced Non-oncogene-addicted NSCLC With PD-L1 ≥50%, Including Longitudinal c-FLIP Assessment in Monocytic MDSCs.

Inclusion Criteria: * Age ≥ 18 years at time of signing Informed Consent Form * ECOG Performance Status of 0-2 * Advanced/metastatic NSCLC without prior treatment in the metastatic setting * Tumor PD-L1 expression with a TPS ≥ 50%, documented through local testing * Measurable disease per RECIST v1.1 * Adequate hematologic and end-organ function Exclusion Criteria: * Ineligibility to receive first line immunotherapy treatment * Patients with driver mutations amenable to molecular targeted therapies in I-line according to the indications of the AIFA